LAPIX Therapeutics Appoints Nimbus CEO Abbas Kazimi to Board of Directors
LAPIX Therapeutics has appointed Abbas Kazimi, Chief Executive Officer of Nimbus Therapeutics, to its Board of Directors as the Company advances its TIM 3/4 agonist program through Phase 1b clinical trials in rheumatoid arthritis (RA) and atopic dermatitis (AD).
LAPIX Therapeutics Announces Completion of Enrollment in Rheumatoid Arthritis Arm of Ongoing LPX-TI641 Clinical Study
LAPIX Therapeutics, a clinical-stage biotechnology company developing a novel immunomodulatory therapy for inflammatory and immune-mediated diseases, today announced the completion of enrollment in the rheumatoid arthritis (RA) arm of its ongoing clinical study evaluating LPX-TI641, the Company's lead therapeutic candidate and a first-in-class oral TIM 3/4 agonist.
